Common Stock, $0.0001 par value per share
- Symbol
- TENX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Tenax Therapeutics, Inc.
TENXNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On July 2, 2026, Tenax Therapeutics, Inc. (the “Company”) issued a press release announcing that it will present results from its Phase 3 LEVEL clinical trial in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026. The Company now expects to report topline data from the Phase 3 LEVEL clinical trial in August 2026.…
Press release in this filing
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 →Company context
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by SPHERA FUNDS MANAGEMENT LTD. regarding TENAX THERAPEUTICS, INC.Oct 13, 2026
- Other EventsOct 8, 2026
- SCHEDULE 13G/A - filed by ING GROEP NV regarding TENAX THERAPEUTICS, INC.Sep 11, 2026
- Regulation FD DisclosureSep 9, 2026
- SCHEDULE 13G - filed by ADAR1 Capital Management, LLC regarding TENAX THERAPEUTICS, INC.Sep 8, 2026
Registered securities in this filing
Tenax Therapeutics, Inc. · 8-K · Filed 2026-07-02
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On July 2, 2026, Tenax Therapeutics, Inc. (the “Company”) issued a press release announcing that it will present results from its Phase 3 LEVEL clinical trial in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026. The Company now expects to report topline data from the Phase 3 LEVEL clinical trial in August 2026. A copy of the press release is attached hereto as Exhibit 99.1.
Filed exhibits (1)
EX-99.1 2 d20457dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 2, 2026 (GLOBE NEWSWIRE) - Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that results from the Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, being held August 28-31 in Munich, Germany. In anticipation of potentially receiving topline results from the LEVEL clinical trial in time for presentation at ESC, an abstract was recently submitted. The Company now expects to report data in August 2026, and in the weeks ahead will proceed towards the planned database lock and statistical analysis. Presentation Details Title: “Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial” Presenter: Professor Sanjiv Shah,…
Open exhibit ↗